The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease by Velders, M.P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23197
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Journal o f Immunotherapy
19(4):245—256 © 1996 L ip p in co tt-R av en  Publishers, Philadelphia
The Role of Monoclonal Antibody Affinity in Tumor 
Immunotherapy Evaluated in In Vivo Models for Minimal 
Residual Disease
Markwin P. Velders, Connie M. van Rhijn, *Ine M. H. A. Cornelissen,
*Goos N. P. van Muijen, Inge H. Briaire, tMikael Dohlsten, Gert Jan Fleuren,
Sven O. Warnaar, and Sergey V. Litvinov
D epartm en t o f  P atho logy, Leiden University H ospita l , Leiden;  *D epartm ent o f  P atho logy , University H ospital 
N ijm eg en , N eijm egen , The Netherlands; and  fT he  Wallenberg Labora to iy , D epartm ent o f  Tumor Im m uno logy ,
University o f  Lund, Sw eden
Summary: To evaluate the role of affinity in monoclonal antibody (mAb>~ 
mediated treatment of carcinomas, we compared the antibodies 17-1A and 
323/A3 that bind with different affinities overlapping epitopes on the epithelial 
adhesion molecule Ep-CAM. This comparison was performed in several mod­
els for minimal residual disease in mice grafted with Ep-CAM transfected B16 
melanoma cells originating from C57BL/6 mice. These cells were either grafted 
subcutaneously or injected intravenously into nude BALB/c mice, or grafted 
subcutaneously in immunocompetent C57BL/6 mice. In the BALB/c subcuta­
neous model, significant therapeutic results (p < 0.05) compared with the 
control mAb were obtained with both mAbs 17-1A and 323/A3. However, 
when treating lung metastases in nude BALB/c mice that had developed after 
intravenous injection of the B16/Ep-CAM tumor cells, only the high-affinity 
323/A3 mAb could significantly (p < 0.05) reduce the number of metastases 
that appeared. In syngeneic C57BL/6 mice grafted subcutaneously with B 16/ 
Ep-CAM cells, a single 323/A3 or 17-1A mAb injection had no effect, in con­
trast to that observed for the nude BALB/c mouse model. However, multiple 
injections of the 323/A3 mAb significantly (p < 0.005) reduced the mean tumor 
volume, although they did not prevent tumor development. The results show 
that in vivo antibody-mediated effector cell activation and subsequent tumor 
cell elimination is determined by mAb affinity and target antigen density. 
Therefore, treatment of minimal residual disease with high-affinity mAb 323/ 
A3 is expected to improve the clinical results obtained with mAb 17-1A. Key 
Words: Monoclonal antibody—Murine models—N K  cells—Affinity.
After a decade of monoclonal antibody (mAb) 
therapy against solid tumors, it can be concluded 
that unconjugated mAbs in general lack the efficacy 
to eradicate large tumor masses. Despite a certain
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ability to localize into the tumor, and to bind to 
tumor cells, several factors such as the size and the 
degree of vascularization of the tumor limit the ac­
cess of the mAb to the target cells and therefore 
affect the cytotoxic potential of mAbs in vivo (1,2). 
However, there could be an important role for 
mAbs as an adjuvant treatment of patients after re­
section of the primary tumor. The use of mAbs in 
eliminating single tumor cells and small tumor nod­
ules that may still be present after tumor resection
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may be useful in prevention of tumor recurrence 
and could offer a more specific therapy with re­
duced side effects, compared with the currently 
used radiotherapy and chemotherapy, As reported 
by Riethmiiller et al. (3), who used murine mAb 
17-1A to treat patients with resected Dukes C colo­
rectal carcinoma (3), a 30% increase in 5-year sur­
vival of treated patients was observed, largely due 
to a reduction of the occurrence of distant me- 
tastases. The results were at least as good as those 
obtained using current chemotherapy schemes 
(4,5), and mAb treatment had significantly lower 
side effects.
In search of more potent mAbs for immunother­
apy of carcinomas, we established that another anti- 
Ep-CAM mAb, 323/A3, which competes with 17-1A 
and has a 40-fold higher affinity, is 100-1,000 times 
more effective against Ep-CAM-positive tumor 
cells in in vitro antibody-dependent cytotoxicity 
(ADCC) and complement mediated cytotoxicity 
(CMC) assays (6). In the current study, we analyzed 
different murine in vivo models to compare the ef­
ficacies of these mAbs for adjuvant therapy of min­
imal residual disease on either subcutaneously (s.c.) 
growing tumors or on lung metastases developing 
after an intravenous (i.v.) injection of tumor cells. 
Immunologically deficient BALB/c nude mice as 
well as fully immunocompetent C57BL/6 animals 
were studied. These models provide an opportunity 
to evaluate the effect of mAb affinity and of differ­
ent treatment regimens to optimize treatment of 
minimal residual disease. In all models, treatment 
with mAb 323/A3 was found to be more effective 
than the treatment with mAb 17-1 A, but especially 
when tumors were treated in syngeneic immuno­
competent mice. This indicates that for future pa­
tient treatment, mAb 323/A3 may also be more ad­
vantageous, as could have been concluded from 
studies in the nude mouse model.
MATERIALS AND METHODS
Cell Lines
M urine B16 melanoma cells derived from 
C57BL/6 mice were obtained from the ATCC. 
B16C215 cells clone D2, B16 cells transfected with 
the Ep-CAM (also known as GA733-2 or C215) 
cDNA have been described previously (7).
Mice
Six-week-old male BALB/c nu/nu or immuno­
competent C57BL/6 SPF mice were obtained from
IFFA Credo (St. Germain-sur-l’Arbresle, France). 
The nude mice were kept in the animal facilities of 
the Academic Hospital Leiden in sterilized cages 
under sterile filter top conditions and were handled 
in a laminar airflow. Sterile food pellets and acidi­
fied sterile water were supplied ad libitum. Immu­
nocompetent animals were kept under standard 
conditions.
Antibodies
The murine IgG2a mAbs 17-1A (8) and 323/A3, a 
switch variant of the original IgGl 323/A3 mAb (9), 
directed against the human epithelial cell adhesion 
molecule Ep-CAM (10,11) were used. MAb 323/A3 
(K.d = 2 x 109 M ~]) has an ~40-fold higher affinity 
for Ep-CAM than mAb 17-1A (K.x -  5 x 107 M ~ x) 
and can prevent mAb 17-1A from binding to Ep- 
CAM (12,13). MAb 175F4 a murine IgG2a directed 
against the MAM-7 antigen, expressed on human 
renal and breast carcinomas, but not on murine B16 
or B16C215 cells, served as a control mAb. The 
antibodies were purified by protein A sepharose 
and ion-exchange chromatography on high-per­
formance liquid chromatography (Pharmacia Bio­
tech B.V., Woerden, The Netherlands) and were 
negative for endotoxin activity by LAL tests.
In Vivo Tumor Models
In the s.c. models, 2.5 x 105 murine B16C215 
cells were injected in the right flanks of the mice on 
day 0. In some experiments, control B16 cells were 
injected in parallel to B16C215 cells into the left 
flanks of the mice. In the Winn-type tumor neutral­
ization assay, 1 x 106 tumor cells were incubated 
with 1 mg/ml mAb in 100 jjlI phosphate-buffered sa­
line (PBS) for 1 h at 37°C. These cells were then 
injected s.c. in the presence of the mAbs. In the 
other s.c. models, mAb therapy started 1 day after 
grafting with an intraperitoneal (i.p.) injection of 40 
or 400 fig mAb. In the multiple injection protocols, 
100 |xg mAb was injected i.p. starting on day 1, and 
additional 100 jxg injections were given on days 4, 8,
11, and 15. Tumor appearance was registered every 
other day and tumor sizes were measured twice a 
week.
In the lung metastasis model, i x 105 or2.5 x 105 
B16C215 cells were injected i.v. in the tail vein of 
nude BALB/c mice on day 0. On day 1, the mice 
received one i.p. injection with either 40 or 400 jxg 
mAb, respectively. On day 21, mice were killed and
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ie tumors that w ere visible on the lung surface 
ere counted. All statistical analyses were per- 
>rmed with the nonparametric Mann-Whitney
iSt.
Flow Cytometric Analysis
To detect binding of murine mAbs 175F4, 17-1 A, 
nd 323/A3 to B 16 or Ep-CAM transfected B16C215 
amor cells, 1 x 106 cells were incubated in 200 julI 
BS + 0.5 bovine serum albumin (BSA) for 1 h at 
°C with 10 ^g/nil mAb. Cells were subsequently 
/ashed three times with PBS/BSA and incubated 
Dr 1 h at 4°C with 100 jjlI fluorescein isothiocyanate 
ibeled rat anti-mouse IgG (Southern Biotechnol- 
'gy Association, Birmingham, AL, U.S.A.) diluted 
: 100 in PBS/BSA. After washing three times with 
>BS/BSA, cells were resuspended in 300 fxl of PBS/ 
ISA containing 1 |xg/ml propidium iodide to dis­
criminate between viable and dead cells. From each 
ample, 10,000 viable cells were examined.
To detect Ep-CAM expression on tumors after 
reatment with various mAbs, the tumor cells from 
nAb-treated mice were isolated by squeezing the 
•esected tumor through a metal grid. The isolated 
umor cells were subsequently cultured for 4 days, 
ifter which all adherent cells were phenotypically 
dentified to the original B16C215 cells. Ep-CAM 
expression was determined using mAb 323/A3,
targets because in nude BALB/c mice, these murine 
cells are probably less immunogenic than human 
xenografts, whereas they also permitted studies in 
immunocompetent C57BL/6 mice. In addition, 
these cells allow a comparison of two tumors from 
one cell line either with or without Ep-CAM expres­
sion. The treatment of parental B16 cells without 
Ep-CAM expression served as a negative control.
The antibodies tested were 323/A3 and 17-1 A, 
both reactive with the Ep-CAM molecule, but with 
different affinity. To investigate whether they rec­
ognize closely located epitopes on Ep-CAM, a com­
petition assay was performed in which both mAbs 
had to compete the 323A3 Fab fragments for bind­
ing to a solid-phase adsorbed pure Ep-CAM. 
As shown in Fig. 1, the 17-1A mAb competes with 
323/A3 Fab fragments, although less effectively 
than the mAb 323A3 itself, which approximately 
corresponds to the previously reported differences 
(40-100 times) in the affinities of these mAbs (6).
To confirm that mAb 175F4 is an appropriate 
control mAb, and to evaluate the binding of 17-1A 
and 323/A3 to the target cells, the binding to B16 
and B16C215 cells was analyzed by flow cytometry. 
All mAbs tested did not bind to B16 cells (data not 
shown), whereas 17-1A and 323/A3 both bound to 
B16C215 cells. However, the high-affinity mAb 323/ 
A3 bound better to B16C215 cells than did the low- 
affinity mAb 17-1A (Fig. 2A).
Cytotoxicity Assays
ADCC and CMC with murine splenocytes or se­
rum, respectively, were performed as previously 
described (6). Splenocytes were obtained from a 
C57BL/6 mouse and were cultured for 3 days in the 
presence of 200 U of interleukin-2 (Cetus, Amster­
dam, The Netherlands), 100 U/ml of murine granu­
locy te-m acrophage colony-stim ulating factor 
(R&D), and 20 \xM |32-mercaptoethanol.
RESULTS
In Vitro Sensitivity of the Ep-CAM Transfected B16
Tumor Cells to the mAb-Mediated
Effector Mechanisms
The results presented in this article concerning 
experimental in vivo therapy for minimal residual 
disease were obtained using the C57BL/6-derived 
murine melanoma cell line B16 and its Ep-CAM 
transfectant B16C215. These cells were selected as
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FIG. 1. A competition assay. In a 96-well enzyme-linked im­
munosorbent assay plate, 500 ng of either monoclonal antibody 
(mAb) 323/A3 ( ♦ ;  an IgG2a variant) or mAb 17-1A (■; IgG2A) 
was tested for binding to a solid-phase adsorbed Ep-CAM in the 
presence of the 323/A3 Fab fragments (0-10,000 ng/well, x  axis). 
The bound mAb was detected using anti-IgG2A-HPRO conju­
gate. T he results are presented as a percent to mAb binding in 
the absence o f  the competing Fab fragments (y axis).
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Using the Ep-CAM transfected B16 tumor cells, 
two potential effector mechanisms that might be ac­
tivated by mAbs in vivo were investigated for their 
efficacy in vitro. ADCC with highly activated 
C57BL/6 splenocytes was performed with 175F4, 
323/A3, and 17-1A mAbs against B16 and B16C2Î5 
cells at effector-target ratios (E/T) of 25, 50, and 
100:1. The results showed that both mAbs 323/A3 
and 17-1A could trigger murine splenocytes to kill 
Ep-CAM-positive tumor cells, although the per­
centage lysis obtained with mAb 17-1A was lower 
than with 323/A3. No ADCC was obtained at E/T 
25:1, whereas ADCC levels at E/T ratios 50:1 and 
100:1 were comparable, indicating a lysis plateau 
was reached at E/T 50:1 for this concentration of 
the mAb. The control mAb 175F4 was unable to
mediate ADCC of the B16C215 cells (Fig. 2B). The 
difference in ADCC between mAbs 17-1A and 323/ 
A3 most likely reflects the differences in binding 
capacity of these mAbs to the B16C215 target cells. 
Another mechanism through which antibodies can 
destroy tumor cells is by activation of the classic 
complement pathway, CMC experiments were per­
formed on 323/A3 mAb-coated B16C215 and B16 
cells with either murine or baby rabbit complement. 
No complement-mediated lysis of murine tumor 
cells was obtained in the presence of murine serum, 
whereas the control baby rabbit complement lysed 
the cells relatively efficiently (Table 1). The activity 
of the murine complement was confirmed by the 
lysis of antibody-coated sheep red blood cells. With 
baby rabbit complement, mAb 323/A3 could medi-
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FIG. 2. A: Flow cytometry histograms of 175F4 (negative control), 17-1 A, and 323/A3 mAb binding to B16C215 Ep-CAM transfected 
murine melanoma cells. B: Antibody-dependent cellular cytotoxicity with granulocyte-macro phage colony-stimulating factor plus in­
terleukin-2 preactivated murine splenocytes and murine IgG2a monoclonal antibodies (mAbs) 175F4 (control), 17-1 A, and 323/A3 against 
B16C215 cells. The percentage lysis is represented on they axis by the specific 5,Cr release after 18 h from B16C215 cells, mediated by 
10 fxg/ml mAb at an effector-target ratio of 50:1. The values shown are means of triplicate samples ±  SD.
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T A B L E  1. C om plem en t lysis assay with murine serum  
and baby rabbit com p lem en t 1:5 diluted with D M E M  
against B16 and  B16C215 cells a t different 323IA3 
m onoclonal an tibody concentrations (in micrograms per  
milliliter): lysis o f  sheep  red blood cells was perform ed
to confirm  the com plem ent activity
Murine serum
Baby rabbit 
complement
B16 2 1 1 1 2 2
B16C215 3 2 1 64 45 12
Sheep red blood cells 89 90 6 92 94 7
Antibody concentration 2 0.2 0 2 0.2 0
ate lysis of B16C215 cells but not of B16 parental 
cells, indicating that the observed lysis was due to 
binding of 323/A3 and that the amount of the 323/A3 
mAb bound to B16C215 cells was adequate to acti­
vate the complement system. The combined in vitro 
results suggest that in vivo, ADCC may be a more 
important mechanism of mAb-mediated kill of 
B16C215 tumor cells than CMC is.
Treatment of Subcutaneous Tumors in BALB/c
Nude Mice
To compare the efficacies of mAbs 17-1A and 
323/A3 for in vivo tumor cell eradication, BALB/c 
nude mice were injected s.c. on day 0 with 2.5 x 105 
murine B16C215 cells into the right flank and with 
2.5 x 105 B16 parental cells into the left flank, fol­
lowed by a single i.p. injection with either 40 or 400 
|xg mAb 24 h after tumor cell inoculation. Within 10 
days, all mice simultaneously developed a B16 tu­
mor on the left flank, indicating that the mAb treat­
ment did not influence the outgrowth of Ep-CAM 
negative tumor cells (data not shown). As depicted 
in Fig. 3, all mice treated with the control 175F4 
mAb also developed a B16C215 tumor within 10 
days after tumor cell inoculation. The first measur­
able B16C215 tumor appearance was not affected 
by treatment with mAb 17-1 A. Treatment of the 
mice with a single injection of mAb 323/A3, how­
ever, postponed first tumor appearance until day 9 
with the 40 fxg injection (Fig. 3A) and until day 11 
with injection of 400 jxg mAb (Fig. 3B). Although 
17-1A did not delay the initial outgrowth of tumors 
in those mice that did come down with tumor, treat­
ment of the mice with one single injection of mAb 
17-1A kept 50% of the mice tumor free, whereas 
323/A3 kept 50-75% of the mice tumor free. There 
was no significant difference between 17-1A and 
323/A3 mAb treatment in this model. None of the 
tumor-free mice developed tumors during the fol­
lowing 3 months after which the experiments were 
terminated.
The mean tumor sizes of all treated mice was 
monitored from day 8 until day 18 after which all 
mice had to be killed because of large tumor vol­
umes of the B16 tumors. Treatment of B16C215 tu­
mors in mice with mAb 17-1A and 323/A3 resulted 
in significantly lower group mean B16C215 tumor 
sizes compared with the control group (Fig. 4). Ad­
ditionally, the mean tumor sizes in the mice that 
developed a tumor were also significantly lower in 
the 17-1A and 323/A3 mAb-treated mice compared 
with the 175F4-treated mice on the same day (Fig. 
4). The difference in mean tumor size on day 18 
between animals treated with either mAb 17-1A or 
mAb 323/A3 was not significant. As expected, the 
mean volumes of B16 Ep-CAM negative control tu­
mors in the mice treated with mAb 17-1A or 323/A3 
were not reduced compared with the B16 mean tu­
mor volumes of the control group treated with mAb 
175F4 (data not shown).
Treatment of Lung Micrometastases in BALB/c
Nude Mice
To simulate the treatment of minimal residual mi­
crometastatic disease in the lung, 1 x 105 B16C215 
tumor cells were injected i.v. in the tail vein on day
0 and groups of 10 mice were treated with one i.p. 
injection of 40 (jug 323/A3, 17-1A, or 175F4 mAb on 
day 1. After 3 weeks, the number of tumors on the 
lung surface were counted. Although the number of 
tumor nodules per lung in the control group varied 
between 12 and 110, treatment with mAb 323/A3 
significantly reduced the average number of lung 
lesions (p <  0.05), whereas 17-1A treatment had no 
effect (data not shown). In a second experiment, 2.5 
x 105 cells were injected i.v. and the mice were 
treated with 400 jxg mAb. The control, but also the 
specific mAb-treated mice developed a greater 
number of lung tumors than in the first experiment. 
However, the results obtained were comparable 
with the first experiment because 17-1A and 175F4 
mAb treatment had no effect, whereas 323/A3 treat­
ment significantly (p < 0.05) reduced the number of 
tumor nodules in the lung compared with 175F4 and 
17-1A mAb treatment (Fig. 5).
Winn Type Tumor Neutralization in 
Immunocompetent Syngeneic C57BL/6 Mice
To study the possibility of the mAb-mediated tu­
mor neutralization in a syngeneic model, a Winn-
J Immunother, Vol. 19, No. 4, 1996
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FIG . 3. T um or appearance in three 
groups o f  eight nude BALB/c mice sub- 
c u ta n e o u s ly  grafted  with 2.5 x 10  ^
B16C215 cells on day 0 and treated with 
one single intraperitoneal monoclonal 
antibody (mAb) injection on day 1. The 
percent o f  tumor-free mice is indicated 
on the y  axis and the observation days 
are indicated  on the * axis. Mice re­
ceived e ith e r  40 fxg (A) or 400 }jug (B) of 
murine lgG 2a mAb 175F4 [control (■), 
mAb 17-1A (ft), or mAb 323/A3 (A)]. 
O bservations of mice for tumor appear­
ance w ere extended until 3 months after 
tum or cell grafting and no additional 
mice developed a tumor during this pe­
riod.
type assay was performed. Tumor cells were prein­
cubated with antibodies before injection into the 
mouse, which allows immediate kill of tumor cells 
by any effector cell present, because all tumor cells 
are present as single cells with a saturating mAb 
density on their surfaces. A Winn-type assay in 
C57BL/6 mice with B16C215 cells preincubated 
with either mAb 17-1 A, 323/A3 or the control mAb 
175F4 indicated that both 17-1A and 323/A3 could
cause a significant (p <  0.05) reduction of the size of 
the tumors developed (Fig. 6). However, no pre­
vention of tumor outgrowth could be obtained, be­
cause all mice developed a B16C215 tumor.
Treatment of sx . Tumors in Immunocompetent
Syngeneic C57BL/6 Mice
The effects of mAb 17-1A and 323/A3 on the 
growth of grafted mostly single tumor cells was in-
J  immunother, Vol. 19, No. 4 t 1996
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FIG. 4. The mean tumor sizes ± SD on day 18 from five groups of eight mice treated with a single injection of either 40 or 400 fj-g 
monoclonal antibody (mAb) 17-1A or 323/A3 1 day after subcutaneous tumor cell grafting (see Fig. 2). Because both 40- and 400-|Xg doses 
resulted in similar mean tumor sizes in the I75F4 control mAb-treated groups, only the mean tumor size obtained with the 400-(xg 175F4 
mAb treatment is presented. Both the group mean (■) and the tumor mean of the mice that developed a tumor (□) are presented. Tumor 
sizes were measured in three dimensions and are expressed in cubic millimeters as indicated on the y axis. The treatment of the group 
is indicated on the * axis.
vestigated in an immunocompetent syngeneic of 100 jxg 175F4 (control), 17-1A, or 323/A3. Three
model. Six groups of eight C57BL/6 mice were in- additional groups received further mAb injections
jected s.c. with 2.5 X 105 B16C215 tumor cells fol- on day 4, 8, 11, and 14. This treatment regimen was
lowed after 24 hours by a single i.p. mAb injection based on our previous observations that mAbs after
MAb treatment
FIG. 5. The number of lung metastases that have developed by day 21 in nude BALB/c mice (three groups, 10 animals each) treated 
with anti-Ep-CAM or control monoclonal antibody (mAb). The number of metastases is shown for individual mice. On day 0, all mice 
received an intravenous injection of 2.5 x 105 B16C215 murine melanoma cells followed by an i.p. injection of 400 |ig mAb on day L 
The mAb injected into the mice of the respective group (17-1 A, 323/A3 or the control 175F4) is indicated on the x  axis, and the number 
of lung metastases is indicated on the y axis. Only 323/A3 mAb treatment resulted in a significantly lower mean number of lung 
metastases on day 21 (p <  0.05 when the group mean numbers of metastases are compared).
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FIG. 6. A Winn-type tumor neutralization assay for treatment of B16C215 cells in immunocompetent C57BL/6 mice. On day 0, 
BI6C215 murine C57BL/6 melanoma cells were incubated before injection with I mg/ml of either murine IgG2a 17-1 A, 323/A3, or 175F4 
(control) monoclonal antibody (mAb) in phosphate-buffered saline at 37°C for 1 h. One hundred microliter mAb solution containing 106 
cells was subsequently injected s.c. in the flank of three groups of C57BL/6 mice. For every mAb treatment (represented on the x axis), 
the mean tumor sizes ± SD (indicated on the y axis) on day 21 are presented in this figure. Mean tumor sizes were measured in three 
dimensions and are presented in cubic millimeters. Mean tumor sizes that differed significantly (p <  0.05) from the mean tumor size in 
the 175F4-treated group are indicated by asterisks.
i.p. injection were present in the tumor until at least 
72 h after injection (2). The first tumors in all groups 
started to appear at day 9, and within 13 days all 
mice had developed a solid tumor (data not shown). 
The mean tumor size in the mice that received a 
single mAb injection did not differ between the 
groups (Fig. 7A). However, mice that received mul­
tiple 323/A3 mAb injections had significantly (p <
0.005) smaller tumors than the 175F4 and 17-1A 
mAb-treated mice (Fig. 7B). At day 15, the obser­
vation of the 175F4- and 17-lA-treated groups had 
to be terminated because the tumor sizes in most of 
these mice exceeded the ethically tolerable size. In 
three separate experiments, only multiple injections 
but not single injections with mAb 323/A3 resulted 
in significantly smaller tumors. Of a total of 30 mice 
that received multiple 323/A3 injections, 3 mice 
stayed tumor free.
Antigen Expression on Tumor Cells After
mAb Treatment
To study the Ep-CAM expression on tumor cells 
from the tumors that had developed despite the 
mAb treatment, tumors from C57BL/6 mice from 
each group were isolated, and the Ep-CAM expres­
sion on tumor cells was determined by flow cyto­
metric analysis with mAb 323/A3 (Fig. 8). Ep-CAM 
expression on tumor cells from mice treated with 
multiple injections of the 323/A3 mAb was found to 
be significantly (p <  0.01) lower in comparison to 
the tumor cells from 175F4 mAb-treated mice. Ep- 
CAM expression on 17-1A- and 175F4-treated tu­
mors was similar to Ep-CAM expression on the 
cells that were maintained in vitro. These results 
suggest that the reduced tumor size observed after 
treatment with 323/A3 was due to the preferential 
elimination of relatively high Ep-CAM-expressing 
tumor cells.
DISCUSSION
The efficacy of treating minimal residual disease 
with mAb 17-1 A, a mAb currently approved for ad­
juvant treatment of patients with resected colon 
carcinoma stage Dukes C, was compared with the 
treatment efficacy of mAb 323/A3 in several differ­
ent in vivo murine models. Both mAbs are directed 
against the human Ep-CAM molecule (10,11). mAb 
323/A3, however, has a 40-fold higher affinity for 
Ep-CAM than mAb 17-1A does (12,13), and was 
previously found to be much more effective than
J  Immunother, Vol. 19, No. 4, ¡996
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FIG. 7. Mean tumor sizes on day 15 of s.c. C57BL/6 derived B16C215 tumors in groups of eight immunocompetent C57BL/6 mice that 
received either single (A) or multiple (B) intraperitoneai (i.p.) injections with murine IgG2a monoclonal antibodies (mAbs) 175F4 
(control), 17-1 A, or 323/A3. The mAb treatment received by the mice is indicated on the x axis and mean tumor sizes ±  SD (in cubic 
millimeters) of the group are indicated on the y axis. Mice received 2.5 x 10s B16C215 Ep-CAM transfected C57BL/6 melanoma cells 
subcutaneously on day 0, followed by either a single i.p. mAb injection of 100 |xg on day 1 (A), or multiple mAb injections on days 1, 
4, 8, 11, and 14 (B), The group with mean tumor size that significantly (p <  0.005) differed from the mean tumor size in the 175F4 
mAb-treated control on day 15 is indicated by an asterisk.
mAb 17-1A in mediating tumor cell kill in vitro by 
ADCC and CMC (6). We (2) and many others have 
successfully treated nude mice xenografted with hu­
man tumor cells with mAbs against human tumor-
associated antigens. In this study, we used a murine 
melanoma cell line transfected with human Ep- 
CAM, which offered the opportunity to study tumor 
treatment in a nude mouse as well as in a syngeneic
J Immunothery Vol. 19, No. 4, 1996
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FIG- 8. A representative flow cytometric determination of Ep- 
CAM expression on B16C2I5 murine melanoma cells isolated 
from monoclonal antibody (mAb)-treated mice by murine 323/A3 
and a fluorescein isothiocyanate conjugated goat anti-murine IgG 
mAb. On day 21, five tumors from each group of B16C2I5 tu­
mor-bearing mice that had received multiple mAb 17-1 A, 323/A3 
o r 175F4 treatment (see Fig. 6B) were isolated, disseminated, 
and cultured for 4 days in vitro. On day 5 after isolation, the 
Ep-CAM expression on these cells was determined by flow cy­
tometric analysis. The relative fluorescence intensity that lin­
early corresponds with the antigen density detected on the cells 
is indicated by the channel numbers and is represented on the x 
axis. The number of cells per channel is indicated on the y axis. 
Ep-CAM expression was determined on B16 and B16C215 cells 
that were maintained in vitro and on isolated B16C215 cells from 
mice treated with mAbs I75F4, 17-1 A, and 323/A3, respectively. 
The percentage of cells that were detected in channel numbers 
10-1,000 are indicated in the boxes.
immunocompetent model. Treatment of human Ep- 
CAM transfected murine tumors in syngeneic mice 
has the advantage that this model is closer to the 
situation in patients than human tumor cell xe­
nografts in nude mice, while still permitting the use 
of mAbs that can be used in patients.
Herlyn and Koprowski showed that complement 
depletion in mice had no influence on mAb- 
mediated tumor cell kill even with human xe­
nografts (14). Based on the presence of complement 
inhibitors on autologous cells, which are generally 
increased on tumor cells (15,16), it is likely that in 
vivo complement-mediated cytotoxicity by mAbs 
hardly contributes to tumor cell kill. Our in vitro
CMC results on autologous B16C215 cells with mu­
rine complement also suggest that in our treatment 
models, CMC plays no major role. On the other
hand, macrophage and monocyte (14) as well as nat­
ural killer (NK) cell depletion (17) in mice was 
found to significantly reduce mAb-mediated ADCC 
against tumors. Therefore, ADCC is expected to be 
the main effector mechanism through which mAbs 
generate a cytotoxic effect against tumor cells in 
vivo. Our ADCC results confirmed that ADCC can 
also act against the Ep-C AM-transfected B16 tumor 
target cells used in this study. We found that it was 
necessary to highly activate the NK cells in vitro to 
obtain ADCC mediated B16C215 tumor cell kill by 
C57BL/6 splenocytes, in agreement with previous
results (17), which indicated a very inefficient 
ADCC-mediated kill of B16 cells by C57BL/6 effec­
tor cells. This most probably is due to the fact that
r
effector NK cells and target cells are syngeneic.
In the model in which BALB/c nude mice were 
s.c. grafted with B16C215 and B16 cells and subse­
quently treated with a single mAb injection, both 
mAb 17-1A and 323/A3 treatments were able to pro­
tect at least 50% of the nude mice against tumor 
formation by B16C215 cells, while not affecting the 
outgrowth of Ep-CAM-negative B16 tumors. With 
respect to the number of mice that remained tumor 
free and the mean tumor sizes, treatment of nude 
BALB/c mice with mAb 323/A3 and mAb 17-1A 
were effective (p <  0.05) compared with the control 
175F4 mAb. Similar effects were observed at both 
mAb concentrations tested, although treatment 
with 400 |xg mAb 323/A3 could prevent tumor for­
mation in 75% of the mice.
The differences in treatment efficacy between 
mAb 17-1A and 323/A3 were more evident in the 
lung model, in which nude BALB/c mice injected
i.v. with B16C215 tumor cells were treated with a 
single intraperitoneal mAb injection. Treatment 
with mAb 323/A3 in this model was found to signif­
icantly reduce the number of lung métastasés com­
pared with treatment with mAb 17-1A and to a con­
trol mAb. The reason why no mice remained tumor 
free in this model may be the previously reported
(17) low number of Fc receptor-positive effector 
cells present in the murine lung. Additionally, in­
jection of tumor cells into the tail vein leads to trap­
ping of the cells in the capillary bed of the lung, 
where the tumor cells can immediately block the 
blood flow through the vessel, thereby becoming 
less accessible for mAbs and effector cells than tu­
mor cells injected into the subcutaneous space, and 
escaping from mAb-mediated kill.
Because nude mice are athymic, their T-cell num­
ber is severely decreased; however, they have sev-
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eral other possibilities for eradicating tumor cells
(18). The percentage of NK cells in peripheral blood 
and spleens of nude mice is much higher than in 
euthymic mice, 18.3 versus 2.5%, respectively
(19.20). Cytolytic activity of NK cells in nude mice 
reaches the highest levels between 5 and 8 weeks 
and is superior to NK activity in euthymic mice
(19.20). NK cells are active against a variety of al­
logeneic tumor cells and are active against major 
histocompatibility complex (MHC) class I-negative 
syngeneic tumor cells (21). NK cell activation can 
be inhibited by a signal transmitted on recognition 
of self MHC class I (22). Correa et al. showed that 
antibodies can activate NK cells through their Fc 
receptors, but that the signal from syngeneic MHC 
class I-positive target cells can significantly re­
duce the extent of ADCC (23). They concluded 
from their experiments that the ADCC level is 
determined by an interplay between the relative 
strengths of the activating and inhibitory signals 
(23). These observations may explain why in our 
model, mAb 17-1A could prevent tumor outgrowth 
in the nude BALB/c mice but not in the syngeneic 
immunocompetent C57BL/6 mice. Treatment of 
B16C215 tumors in allogeneic BALB/c nude mice, 
where the NK activation by mAb 323/A3 and 17-1A 
is not inhibited by syngeneic MHC class I, resulted 
in an efficient kill of tumor cells. However, in the 
C57BL/6 mice, the syngeneic MHC class I inhibi­
tory signal may decrease the efficacy of NK cell- 
mediated ADCC. A high mAb affinity will enhance 
mAb binding to the tumor cells and therefore give a 
stronger activation signal to NK cells. This may 
explain why in our syngeneic C57BL/6 mice, a sig­
nificant reduction of B16C215 tumor volume was 
only found after multiple treatments with 323/A3 
and not with single treatment or multiple treatments 
with mAb 17-1A. However, using very high anti­
body concentrations on single tumor cells, as in the 
Winn-type assay, mAb 17-1A also may trigger NK 
cells, leading to lysis of grafted tumor cells, al­
though less efficiently than in BALB/c mice. In 
BALB/c mice s.c. grafted with human LSI80 colo­
rectal carcinoma cells, another allogeneic model 
studied previously both 17-1A and 323/A3 mAb 
treatment also resulted in cures in >50% of the mice
(2). Therefore, the differences observed between 
tumor eradication with mAbs in nude BALB/c mice 
and immunocompetent C57BL/6 mice, respec­
tively, are likely to be dependent on the genetic 
background of the tumor cells as well as on the total 
numbers of NK cells and other effector cells.
On the residual tumor cells in five C57BL/6 mice 
after treatment with mAb 323/A3, Ep-CAM expres­
sion was significantly decreased compared with Ep- 
CAM expression on B16C215 tumor cells treated 
with mAb 17-1A, 175F4, or in vitro. This observa­
tion suggests that only tumor cells with high Ep- 
CAM expression were killed by the multiple 323/A3 
mAb injections. Our results in C57BL/6 mice are in 
contrast to the observation in nude BALB/c mice 
by Johansson et al. (1), who found no difference in 
Ep-CAM expression between tumor cells isolated 
from mAb-treated mice versus control mice after 10 
daily mAb injections with mAb C215, which is also 
directed against Ep-CAM. In the xenograft model 
by Johansson et al., NK cells were activated 
through mAb binding, but did not receive inhibitory 
signals from self MHC molecules. This may have 
led to a higher activation of NK cells, and subse­
quently to a better kill of tumor cells, including low 
Ep-CAM -expressing cells. In our syngeneic 
C57BL/6 model, however, only the high-expressing 
tumor cells may have been able to bind enough 
high-affinity mAb to overcome the self MHC class I 
inhibitory signal and could activate the NK cells to 
kill the tumor cells. Exploiting this hypothesis, only 
tumor cells with high Ep-CAM expression would be 
eliminated and the eventually outgrowing tumor 
will consist of tumor cells with a relatively low Ep- 
CAM expression level. If correct, this observation 
supports the selection of high-affinity mAbs for 
treatment of patients. Because NK cells are impor­
tant ADCC effectors (17) and negative signals 
through MHC class I recognition are likely to re­
duce the efficacy of low-affmity mAbs, it becomes 
important to use high-affinity mAbs in therapy of 
patients. In addition, other effector cells such as 
monocytes, macrophages, and granulocytes may 
also play a role in mAb treatment of patients.
From the present study, we conclude that tumor 
therapy with the high-affinity 323/A3 was more ef­
fective than treatment with the low-affinity mAb 
17-1 A. The Winn-type tumor neutralization assay 
indicated that immediate mAb treatment of single 
tumor cells is most effective, and that even a 1-day 
delay of mAb treatment against single tumor cells 
reduces the final outcome of the treatment. In the 
syngeneic immunocompetent C57BL/6 mice, mAb- 
mediated tumor cell elimination was reduced, pos­
sibly due to inhibition of NK cell activation by self 
MHC class I recognition. Only the high-affinity 
mAb 323/A3 was effective against high antigen- 
expressing tumor cells. In addition, our in vivo
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treatment results with mAbs alone support previous 
recommendations (17,24) to use high-affinity mAbs 
in combination with cytokines to improve the re­
sults obtained so far in patients with mAb 17-1A (3).
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